Purchase Order 75F40125P00116
Award Date
7/22/25
Potential Completion Date
2/28/26
Potential Value
$107K
Federal Agency
Food and Drug Administration
Awardee
Olink Proteomics Inc.
Ultimate Awardee
Not listed
PSC Category
B529 - Special Studies/Analysis- Scientific Data
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Waltham, MA 02453, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
6
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Food and Drug Administration (FDA) awarded a $99,413.00 firm-fixed-price purchase order contract to Olink Proteomics Inc., a foreign-owned, for-profit biotechnology company, to conduct cardiotoxicity biomarker analysis on plasma samples from cancer patients. The contract has an ultimate completion date of September 29, 2025. This contract was awarded under a competitive solicitation that was set aside for small businesses under NAICS code 541380 - Testing Laboratories and Services....
The Food and Drug Administration (FDA) awarded a $94,500 firm fixed-price purchase order to Olink Proteomics AB, a foreign-owned manufacturer of protein biomarker analysis technologies and services. The contract is for quantitative proteomics measurement of cardiotoxicity biomarkers in 150 human plasma samples using Olink's proprietary Explore 1536 multiplex analysis platform. This purchase order was awarded without a set-aside and is not associated with a larger contract vehicle. Olink...
This is a $79,345.00 firm-fixed-price purchase order awarded by the Food and Drug Administration (FDA) to Olink Proteomics Inc., a foreign-owned, for-profit biotechnology company. The contract is for quantitative proteomics measurement of human COVID-19 plasma samples, which supports the FDA's research efforts related to the COVID-19 pandemic. Olink Proteomics specializes in protein biomarker discovery and has provided a range of proteomics instruments, reagents, and analysis services to various...
The Department of Health and Human Services Food and Drug Administration awarded a $87,620 purchase order to Olink Proteomics Inc. of Waltham, Massachusetts. The firm fixed price contract is for quantitative proteomics measurement of 100 human COVID-19 plasma samples. Performance will take place in Waltham from July 18, 2023 through December 8, 2023. The solicitation sought quantitative proteomics measurement of the specified plasma samples, as described in the attached combined synopsis and...
The Department of Health and Human Services (HHS) Food and Drug Administration (FDA) awarded a firm-fixed price purchase order contract to Olink Proteomics Inc. for $115,920.00 to provide protein biomarker analysis of cardiotoxicity in human plasma samples. The contract has a completion date of December 31, 2022 and was awarded on June 9, 2022. No set-aside designation was used for this award. Olink Proteomics is a biotechnology company that specializes in proteomics solutions and has held...
This firm fixed price purchase order contract was awarded by the Food and Drug Administration (FDA) to Olink Proteomics AB, a foreign-owned for-profit manufacturer based in Sweden. The $75,718 contract is for the provision of proteomics analysis services, including the analysis of plasma samples to support biomedical research across disease areas such as cancer, cardiovascular disease, infectious disease, and COVID-19. Olink has previously provided similar services to federal agencies like the...
This federal contract award, valued at $24,775.29, was issued by the National Heart Lung and Blood Institute (NHLBI), a civilian agency within the National Institutes of Health (NIH), to Olink Proteomics Inc., a foreign-owned, for-profit biotechnology company located in Waltham, Massachusetts. The contract requires Olink to provide proteomic kits to isolate and quantify proteins in plasma and bronchiole alveolar lavage samples. This is a firm fixed-price purchase order contract with a completion...
The National Institutes of Health (NIH) Clinical Center's Critical Care Medicine Department (CCMD) has awarded a firm-fixed-price purchase order contract valued at $44,646.78 to Olink Proteomics Inc., a foreign-owned for-profit biotechnology company based in Waltham, Massachusetts. The contract is for the procurement of Olink Signature Q100 system reagents, including Olink Target 96 Inflammation, Olink 96.96 IFC for Protein Expression, and Olink Target 96 Organ Damage reagents. These reagents...
This is a $30,625.00 firm fixed-price purchase order contract awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute on Aging to Olink Proteomics Inc., a foreign-owned for-profit biotechnology company. The contract is for Olink's EXPLORE HT proteomics analysis service, which provides high-multiplex protein biomarker discovery capabilities. Olink Proteomics has a history of providing proteomics instruments, reagents, and analysis services to...
This federal contract award, valued at $10,558.00, was issued by the National Institutes of Health (NIH) Clinical Center to Olink Proteomics Inc., a foreign-owned, for-profit biotechnology company based in Waltham, Massachusetts. The contract is for a service agreement to provide the Olink Signature Q100 System, which is an advanced proteomics instrument used for protein biomarker discovery and analysis. The contract has a period of performance from August 5, 2025 to August 4, 2026 and is a firm...